OM_Logo_kurz_grau.png
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
26 sept. 2024 06h00 HE | OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19 août 2024 08h00 HE | ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
Transparency Market Research
Ashwagandha Market is Likely to Reach USD 1.9 billion by 2034 at a CAGR of 9.2% | Report Analysis by Transparency Market Research Inc.
12 août 2024 05h24 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The global ashwagandha market (아슈와간다 시장) was projected to attain US$ 692.9 million in...
Pet Independent Innovation Awards.jpg
Snif-Snax Wins “Natural Dog Treat Product of the Year” In 2024 Pet Innovation Awards
06 août 2024 08h00 HE | Pet Innovation Awards
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The 2024 Pet Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly...
Derm logo.png
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 mai 2024 10h00 HE | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
27 févr. 2024 10h00 HE | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin...
GMILogo_Vertical-Gradient.png
Basil Extracts Market to exceed $1.5 Bn by 2032, Says Global Market Insights Inc.
17 janv. 2024 20h30 HE | Global Market Insights Inc.
Selbyville, Delaware, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The basil extracts market valuation is anticipated to reach USD 1.5 billion by 2032, as reported in a research study by Global Market...
Transparency Market Research
Animal Drug Compounding Market is Predicted to Reach USD 2.4 billion by 2031, Registering a 7.4% CAGR: TMR Report
04 oct. 2023 03h47 HE | Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The animal drug compounding market acquired US$ 1.1 billion in 2021. The market is likely...
ihl_logo.png
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
03 mai 2023 07h30 HE | Incannex Healthcare
MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data...
The Dry Eye Drink by Bruder
Bruder Healthcare Now Exclusive Licensor of the Dry Eye Drink™ -- First and Only Ophthalmic Anti-Inflammatory Hyper-Hydrating Drink
13 févr. 2023 10h00 HE | Bruder Healthcare
ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Bruder Healthcare, a Hilco Vision Company, announced an exclusive licensing agreement with Baton Rouge-based Dry Eye Drink LLC, the manufacturer of a...